Market Overview:

The global T-cell therapy market is expected to exhibit a CAGR of 16.9% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

T-cell therapy is an immunotherapy approach, known as adoptive cell transfer (ACT), wherein the immune cells from the body of the patient are utilized to treat cancer. It involves collecting T-cells via apheresis and re-engineering them in a laboratory. These re-engineered cells are then multiplied and infused into the body to recognize and kill cancer cells with targeted antigens on their surface. Presently, a growing number of T-cell therapies are undergoing clinical studies. One such study includes the development of an off-the-shelf approach that collects immune cells from healthy donors and makes them available for immediate use.

The growing consumption of tobacco products, unhealthy dietary patterns and sedentary lifestyles are among the key factors escalating the risk of developing cancer. This, in confluence with the rising number of individuals diagnosed with bone marrow and blood-forming tissue diseases, represents one of the major factors catalyzing the demand for T-cell therapies. Moreover, the mass spread of coronavirus disease (COVID-19) has encouraged researchers worldwide to adopt T-cell therapies for treating high-risk patients. Apart from this, the rising awareness among individuals about medical services, in confluence with favorable government policies and regulations, is also propelling the market growth. Additionally, the United States Food and Drug Administration (USFDA) recently approved T-cell therapies to treat children with acute lymphoblastic leukemia (ALL) and adults with advanced lymphomas. This, in turn, is anticipated to provide lucrative opportunities to manufacturers and stimulate the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global T-cell therapy market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on modality, therapy type and indication.

Breakup by Modality:

• Research
• Commercialized
   

Breakup by Therapy Type:

• CAR T-cell based
• T Cell Receptor (TCR) based
• Tumor Infiltrating Lymphocytes (TIL) based
   

Breakup by Indication:

• Hematologic Malignancies
  • Lymphoma
  • Leukemia
  • Myeloma
• Solid Tumors
  • Melanoma
  • Brain and Central Nervous System
  • Liver Cancer
  • Others
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Aurora Biopharma Inc., bluebird bio Inc, Bristol-Myers Squibb Company, Fate Therapeutics, Gilead Sciences Inc., Merck KGaA, Mustang Bio Inc. (Fortress Biotech Inc.), Novartis AG, Pfizer Inc., Sorrento Therapeutics Inc. and TCR2 Therapeutics.

Report Coverage: